Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 1/20 | 0.49 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577206 | 0.87 | CCR3 (0.56) | ALDH1A1CCR3CYP2C9CYP2C19HTR2B | |
| SCHEMBL22442303 | 0.87 | FAAH (0.56) | FAAHKDM4ELMNAMAPTALDH1A1 | |
| SCHEMBL18915165 | 0.85 | FAAH (0.55) | FAAHKDM4ELMNAMAPTALDH1A1 | |
| SCHEMBL4576925 | 0.85 | MEN1 (0.60) | KDM4EMAPTALDH1A1CCR3CYP2C9 | |
| SCHEMBL2243090 | 0.85 | ALDH1A1 (0.64) | FAAHLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL5169485 | 0.83 | FAAH (0.63) | FAAHKDM4ELMNAMAPTOPRM1 | |
| SCHEMBL4576966 | 0.82 | FAAH (0.61) | FAAHKDM4ELMNAMAPTGRIN2B | |
| SCHEMBL22371834 | 0.77 | GPR183 (0.44) | KDM4EMAPTALDH1A1CCR3CYP2C9 | |
| SCHEMBL4578120 | 0.76 | L3MBTL1 (0.81) | FAAHKDM4ELMNAMAPTALDH1A1 | |
| SCHEMBL16113579 | 0.76 | GPR119 (0.61) | FAAHKDM4ELMNAMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | FAAH 835/4885KDM4E 1161/4885LMNA 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.